ACAD
ACADIA Pharmaceuticals Inc
20.70$
-6.8%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 99.7% | 98.7% | 97.6% | 97.1% | 97.4% | 97.1% | 91.7% | 88.2% | 86.4% | 82.3% | 79.0% | 67.9% | |
| 19.0% | 46.0% | 29.2% | 18.1% | 24.9% | 24.2% | 41.7% | 21.1% | 19.5% | 25.2% | 26.9% | 11.4% | |
| 99.1% | 97.0% | 94.3% | 88.8% | 87.7% | 89.1% | 80.7% | 74.4% | 70.9% | 58.6% | 63.6% | 52.4% | |
| 0.3% | 0.7% | 1.3% | 4.8% | 5.1% | 4.8% | 6.4% | 9.3% | 10.7% | 13.7% | 8.8% | 9.5% | |
| 0.0% | 0.0% | 0.7% | 1.4% | 0.8% | 0.8% | 1.2% | 1.1% | 1.1% | 4.8% | 1.8% | 2.2% | |
| 0.2% | 1.0% | 0.5% | 0.7% | 0.6% | 0.4% | 1.2% | 9.5% | 10.5% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | 0.0% | – | – | |
| 0.0% | 0.0% | 1.3% | 1.4% | 0.8% | 0.3% | 0.1% | – | – | 8.7% | 10.1% | 7.0% | |
| 4.9% | 10.0% | 7.6% | 12.8% | 11.3% | 10.7% | 19.9% | 22.7% | 31.9% | 42.4% | 38.3% | 21.5% | |
| 4.9% | 9.9% | 7.6% | 12.8% | 11.0% | 9.6% | 13.5% | 13.7% | 21.4% | 33.9% | 33.2% | 17.7% | |
| – | – | – | – | – | 0.4% | 0.6% | 1.2% | 1.6% | 1.3% | 0.8% | 0.7% | |
| 0.6% | 0.8% | 0.7% | 2.3% | 0.6% | 0.9% | 1.1% | 1.0% | 2.2% | 2.3% | 1.4% | 0.7% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 95.1% | 90.0% | 92.4% | 87.2% | 88.7% | 89.3% | 80.1% | 77.3% | 68.1% | 57.6% | 61.7% | 78.5% | |
| -153.1% | -298.6% | -166.4% | -318.2% | -271.9% | -217.6% | -253.7% | -307.6% | -403.1% | -324.6% | -185.6% | -115.9% | |
| 29.9% | 45.4% | 20.6% | 31.9% | 23.4% | 18.8% | 20.1% | 22.9% | 27.5% | 21.9% | 14.0% | 11.0% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.